

Do not write in this box



PATIENT LABEL

**CHEMOTHERAPY-INDUCED ANEMIA
ERYTHROPOIETIN ORDER SHEET**

DATE & TIME	ORDER
	Diagnosis
	<input type="checkbox"/> Chemotherapy-induced Anemia (excludes AML & CML) <p style="margin-left: 150px;">Eligibility begins with the first dose of chemotherapy within a course of chemotherapy. Eligibility ends 8 weeks after last chemotherapy within a course of chemotherapy.</p>
	<input type="checkbox"/> Current Hgb/Hct _____ (Hgb must be < 10 immediately prior to initiation of ESA therapy) <input type="checkbox"/> Status post peripheral stem cell transplant
	Parameters for beginning treatment
	<input type="checkbox"/> Pre-treatment Iron Studies completed. Pre-treatment Iron Studies include: Iron Study (includes Iron, TIBC, and % Saturation), Ferritin, Erythropoietin level, Soluble Transferrin Receptor, Reticulocyte Count. If % Saturation <20% or Ferritin <100 ng/mL, begin FESO4 325 mg BID or consider IV iron.
	Medication Orders
	<input type="checkbox"/> Epoetin (Procrit™) _____ units subq every week x _____ weeks (up to 4 week maximum per order)
	<input type="checkbox"/> Darbepoetin Alfa (Aranesp™) _____ mcg subq every _____ week(s) x _____ weeks (up to 4 week maximum per order)
	Lab – CBC Frequency
	<ul style="list-style-type: none"> • Hgb/Hct prior to each dose (During first 4 weeks of treatment, Hgb may exceed 10, if ≤ 1 g/dL rise in <u>any</u> 2 week period)
	<input type="checkbox"/> CBC with each dose
	<input type="checkbox"/> Other _____
	<ul style="list-style-type: none"> • Hold if Hgb ≥ 10 after four weeks of treatment.
	<input type="checkbox"/> For patients receiving chemotherapy: Patient was educated according to REMS requirements
	<input type="checkbox"/> The REMS Program Acknowledgement Form has been signed by the patient and REMS- enrolled provider
	Physician Signature _____
	Date _____

**CHEMOTHERAPY-INDUCED ANEMIA
ERYTHROPOIETIN ORDER SHEET**

Overview of ESA National Coverage Decision

Initiate ESA when Hgb <10

After 4 weeks		After 8 weeks	
If:	Then:	If:	Then:
Hgb <10 AND Hgb rise from baseline ≥ 1	Continue ESA at same dose		
Hgb ≥ 10	ESA no longer covered ESA may be resumed if Hgb again drops below 10		
Hgb <10 AND Hgb rise from baseline <1	Increase ESA dose by 25%	Hgb rise ≥ 1	Continue ESA at same Dose
		Hgb rise <1	ESA no longer covered

During ANY 2-week period

If:	Then:
Hgb rise ≤ 1	Continue ESA and re-assess Hgb
Hgb rise >1 AND Hgb <10	Reduce ESA dose by 25%
Hgb rise >1 AND Hgb ≥ 10	ESA no longer covered If Hgb again falls below 10, may reinstitute ESA with a 25% dose reduction

The maximum dose for the first 4 weeks is 1,800 units/kg for epoetin and 9 mcg/kg for darbepoetin.

ESA treatment meeting the above requirements may be continued for 8 weeks following the completion of the final dose of myelosuppressive chemotherapy in a chemotherapy regimen.

Following the first 4 weeks of ESA treatment, a hemoglobin level of <10 g/dL must be documented immediately prior to each dose of an ESA.